Navigation Links
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant prostate cancer (mCRPC). Data presented showed that ipilimumab monotherapy or in combination with radiotherapy was clinically active and generally well-tolerated. Preliminary evidence of anti-cancer activity showed that 21 percent of patients (7 of 33) experienced decreases in prostate-specific antigen (PSA) serum levels of over 50 percent, with median duration of PSA responses of 4.8 months. This included one patient treated at the highest dose with a complete response (measured by both PSA and RECIST criteria) ongoing over one year. Two additional patients had PSA reductions of more than 30 percent within 12 weeks of treatment. The interim results were described in an oral presentation by investigator Tomasz M. Beer, M.D., the Grover C. Bagby Endowed Chair for Prostate Cancer Research and Associate Professor of Medicine from Oregon Health & Science University Cancer Institute, at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago. (Abstract #5004)

"These initial data in patients with metastatic castration resistant prostate cancer demonstrated preliminary anti-tumor activity, including durable response, and is suggestive of a safety profile at the optimal ipilimumab regimen similar to that observed in our melanoma program," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Radiotherapy is routinely used for palliative treatment in patients with metastatic castrat
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
10. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , Oct. 16, 2014 The ... guidance on the application of single-use, or ... pharmaceutical and biopharmaceutical products with the publication ... Application of Single-Use Systems in Pharmaceutical ... described as single-use systems (SUS) or single-use ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & ... under 3 weeks away from hosting their co-located ... Oral Drug Formulation Innovations Summit taking place ... San Diego, CA. November,s events ... organizations in streamlining the bioequivalence testing process, as well ...
(Date:10/16/2014)... PHILADELPHIA , Oct. 16, 2014 Ninety ... (ALL) who had relapsed multiple times or failed to ... an investigational personalized cellular therapy, CTL019, developed at the ... The results published today in The ... new data, which builds on preliminary findings presented at ...
Breaking Medicine Technology:PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Health Corp. (Nasdaq: WBMD ) today announced the ... amount of 2.50% Convertible Notes due 2018 (including $50 million ... full of the initial purchaser,s over-allotment option).  The notes were ... under the Securities Act of 1933.   The ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com ... is available in its catalogue: ... Price cuts set to negatively impact both ... http://www.reportlinker.com/p0360216/Spain-Pharmaceutical-Market-Overview – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies 2
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... allege the IUD caused women to sustain serious injuries ... the uterus continue to mount in U.S. courts, Bernstein ... issued by the U.S. Judicial Panel on Multidistrict Litigation ... are now pending in the multidistrict litigation underway in ...
(Date:10/18/2014)... One major trend upcoming in this market is ... making efforts to encourage people to donate organs. The ... process more transparent and easy. , Analysts forecast the ... at a CAGR of 16.85 percent over the period ... drivers in the market is an increase in the ...
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... continue to mount in a mass tort litigation ... Pleas, Bernstein Liebhard LLP reports. According to court ... in the proceeding on behalf of Risperdal patients ... gynecomastia (male breast growth), due to their use ...
(Date:10/18/2014)... Oct. 18, 2014 (HealthDay News) -- Even determined dieters ... of healthy foods nearby, researchers say. Their new ... had metabolic syndrome (a combination of risk factors that ... And, all were told by their doctors to make ... The participants were involved in a clinical trial ...
(Date:10/18/2014)... is known to most people, ASP.NET hosting is a ... Cheap Hosting USA has compared many professional web ASP.NET ... JustHost are among the most reliable companies in the ... a good ASP.NET supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 3Health News:Dieters May Be Thwarted by Absence of Healthy Foods 2
... News) -- Media multitasking -- the use of more than ... -- may have some positive effects, a new study suggests. ... which is especially common in young people and could include ... or social networking -- have received widespread publicity. But ...
... CINCINNATINew research at the University of Cincinnati (UC) ... a complex process that can provide cells with ... circumstances autophagy can protect tumor cells from chemotherapy, ... time in a hidden, dormant, metastatic state. ...
... , SUNDAY, April 15 (HealthDay News) -- A ... regions linked to fractures and osteoporosis. Variations in ... bone-weakening disease, the investigators reported in a new study published ... . The study authors added that their findings could ...
... appear to be rising, especially among high school students, ... is alarming and indicates more coaches and athletic trainers ... the game, according to researchers based at the University ... the number of football-related brain injuries with permanent disability ...
... Cancer is much more likely in the elderly than the ... disease and the often-toxic side effects of treatment. But ... The University of Texas Health Science Center at San Antonio shows ... younger patients can be used to help the elderly, with less ...
... , FRIDAY, April 13 (HealthDay News) -- In a new study ... of sun damage, middle schoolers showed evidence of levels of UV ... Not only can the technology spot who is most vulnerable ... noted, but it could also be used as a powerful deterrent ...
Cached Medicine News:Health News:Media Multitasking Might Have Mental Upside 2Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Certain Genetic Regions May Be Tied to Osteoporosis 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3Health News:Even Young Teens Show Signs of Sun Damage 2Health News:Even Young Teens Show Signs of Sun Damage 3Health News:Even Young Teens Show Signs of Sun Damage 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: